Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

The company behind popular weight-loss drugs failed to disclose millions of pounds it paid to healthcare groups and patient ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

For many struggling with weight management, new medications like Wegovy, Mounjaro, and Saxenda have been seen as ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Weight-loss drugs have been rolled out by the NHS, but many are buying them through social media and online pharmacies ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...